Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

Daniele Armenia, Domenico Di Carlo, G. Maffongelli, Vanni Borghi, Claudia Alteri, Federica Forbici, Ada Bertoli, Caterina Gori, Massimo Giuliani, Emanuele Nicastri, Mauro Zaccarelli, Carmela Pinnetti, Stefania Cicalini, Gianpiero D'Offizi, F. Ceccherini-Silberstein, Cristina Mussini, Andrea Antinori, M. Andreoni, Carlo Federico Perno, Mm Santoro

Research output: Contribution to journalArticlepeer-review


Objectives: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods: Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results: DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2% and 84.3% in drug-naïve and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-naïve patients [>500 000 HIV-1 RNA copies/mL: median [interquartile range (IQR)] 6.1 (5.1-10.3) months; 100 000-500 000 copies/mL: median (IQR) 4.9 (3.8-6.1) months;

Original languageEnglish
Pages (from-to)21-32
JournalHIV Medicine
Issue number1
Publication statusPublished - Jan 2017


  • Baseline viraemia
  • Darunavir
  • Darunavir dosage
  • Drug resistance
  • Virological response

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy


Dive into the research topics of 'Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens'. Together they form a unique fingerprint.

Cite this